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(-8.2mmHg, n = 146), valsartan (-7.9mmHg, n = 142) and irbe-
sartan (-9.9mmHg, n = 145), p < 0.05 in each comparison. The
proportion of patients with controlled BP were 56.0% (95%
conﬁdence intervals; 47.4%–64.1%), 41.7% (33.7%–50.2%),
32.6% (24.8%–40.8%), and 52.1% (44.0%–60.8%), with
olmesartan, losartan, valsartan and irbesartan respectively at
week 8 (p < 0.05 olmesartan vs losartan and valsartan). Mean
costs were the same for all options considered, yielding olme-
sartan as the dominant option with a cost per successfully treated
patient lower (92.43€ (88.2€–96.6€)) than with the other drugs;
124.12€ (120.0 €–128.3€), 158.77€ (154.8€–162.8€) and 99.35€
(95.1€–103.6€), for losartan, valsartan and irbesartan, respec-
tively. CONCLUSIONS: Olmesartan showed a more favourable
pharmaco-economic proﬁle than losartan and valsartan in the
short-term treatment of mild to moderate essential hypertension
in Spain. Irbesartan was not statistically inferior than olmesar-
tan. Long-term studies are needed to conﬁrm these ﬁndings.
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OBJECTIVES: Abdominal aortic aneurysm (AAA) is a common
disease, particularly among elderly men. Rupture of AAA is asso-
ciated with high mortality, causing about 1% of all fatalities in
men over 60 years of age. Most patients with ruptured AAA die
before they come to surgery and the overall mortality is about
80%, compared to a reported mortality during elective surgery
of 0–9%. Early detection by screening has therefore been advo-
cated and the objective of this study was to evaluate the long-
term cost-effectiveness of different screening strategies for AAA.
METHODS: A Markov cohort simulation model was developed
and different screening strategies in terms of age and risk pro-
ﬁles of the screened population and re-screening were analysed.
Assumptions and variables in the model were based on a sys-
tematic review of the literature. The cost per life year gained was
used as main outcome measure. RESULTS: The cost per life year
gained for the different screening strategies ranged from $8309
to $14,084 and was estimated to $10,474 when 65-year-old men
were screened once. Sensitivity analyses showed that the results
were robust. Variations of risk of rupture among screened and
non-screened and long-term survival affected the cost-effective-
ness substantially. The cost-effectiveness was rather insensitive to
variations in cost of screening, cost of surgery and attendance
rate. CONCLUSIONS: Screening for AAA may be cost-effective
in 65-year-old men, while screening younger men with a re-
screening could be equally cost-effective with the advantage of
more life years gained. Some aspects need to be characterized in
further detail, particularly quality of life effects related to screen-
ing for AAA, age-speciﬁc natural course of AAA and age-speciﬁc
long term survival.
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OBJECTIVES: Congestive heart failure (CHF) is the leading
cause for hospitalization in the elderly. In a meta-analysis of 
16 randomized controlled trials (RCT) investigating disease
management programs (DMP) in the treatment of CHF, we 
previously demonstrated a statistically signiﬁcant reduction 
in mortality and rehospitalization, but cost-effectiveness of 
DMPs remains uncertain. Therefore, we sought to evaluate life
expectancy and life long medical costs for DMPs. METHODS:
Design: Cost and cost-effectiveness analysis using a 6 state
Markov Model representing the number of prior hospitalizations
(h = 1 to h = 4+) and death. Data sources: Pooled efﬁcacy data
from our meta-analyses of RCTs, SOLVD registry data for age-
dependent hospitalizations and mortality rates adjusted for 
additional beneﬁt from beta-blocker therapy and reimbursement
costs in the Australian health care system. Target population:
Patients that have been admitted with CHF. Time horizon: life-
time. Perspective: societal. Intervention: conventional therapy
and DMP. Outcome measures: Life years gained (LYG) and life-
long direct medical costs. RESULTS: For a population aged 73
at onset of CHF (27% female, 33% on beta-blocker), our model
yielded, on average, a remaining life expectancy of 3.24 years
for conventional therapy and 3.38 years for DMP. Mean undis-
counted lifetime costs per patient were estimated at 11,600€
and 12,700€ respectively. The discounted incremental cost-
effectiveness ratio (ICER) of DMP vs. conventional care was
8813€ per LYG. Assuming the beneﬁt due to DMP lasting for 5
years after the end of the actual intervention would lead to addi-
tional 5 life-months and reduce ICER to 4021€/LYG. CON-
CLUSIONS: Based on our decision analysis, DMPs prolong life,
but increase life-time costs. A cost-saving effect of DMPs as sug-
gested in some original studies could not be conﬁrmed. However,
even under conservative assumptions regarding the duration of
DMP, these programs are cost-effective when compared to other
well-accepted medical interventions in heart disease.
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OBJECTIVES: Sinus Node Disease (SND) is a common indica-
tion for implantation of a permanent pacemaker. In case of 
subsequent development of atrioventricular block (AVB) it is nec-
essary to upgrade atrial pacemaker (AAI) to dual-chamber
(DDD). The aim of the study was to evaluate the inﬂuence of
atrial ﬁbrillation (AF) history on the risk of AVB development in
patients with SND and permanent AAI and its impact on pacing
therapy costs. METHODS: Data of 752 patients with SND who
had AAI implanted between 1993 and 1997 were identiﬁed. The
history of AF was established on the basis of preoperative exam.
The records of patients were examined to ﬁnd cases that required
further procedure to upgrade AAI to DDD. The cost analysis was
performed to assess the strategy of primary DDD implantation
in those patients with SND that would receive AAI as a stan-
dard. The costs taken into consideration were: pacemaker, leads,
implantation procedure, hospitalization. The analysis of sensi-
tivity for main partial costs was performed, future costs were 
discounted. RESULTS: In the whole group of 752pts–144pts
(19.1%) required the upgrade procedure. A total of 417pts
(55.5%) had a history of AF. A total of 105pts had the subse-
quent DDD pacemaker implanted in the AF group (25.2%) and
39 in the group with no AF history (11.6%). There were savings
of 82€ per patient, in the primary AAI implantation arm, in the
whole group and 190€ Euro in the no-AF group whereas both
strategies were equal in the group with AF history. CONCLU-
